Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jubilant PharmovaBOM:530019 +0.21%71 Days Payable is 157.87 as of Mar. 2026, which is 31% above its 10-year median of 120.23. GuruFocus rates BOM:530019 with a GF Score™ of 71/100 and a GF Value™ of ₹1,060.00 (Fairly Valued). The stock has 5 warning signs investors should review. Among 925 Drug Manufacturers companies, Jubilant Pharmova ranks better than 75.14% on this metric.
The historical rank and industry rank for Jubilant Pharmova's Days Payable or its related term are showing as below:
BOM:530019'
s Days Payable Range Over the Past 10 Years
Min: 102.98 Med: 120.23 Max: 233.67
Current: 149.06
During the past 13 years, Jubilant Pharmova's highest Days Payable was 233.67. The lowest was 102.98. And the median was 120.23.
BOM:530019's Days Payable is ranked better than 75.14% of 925
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs BOM:530019: 149.06
Jubilant Pharmova's Days Payable
increased
from Mar. 2025 (146.44) to Mar. 2026 (157.87).
It may suggest that Jubilant Pharmovadelayed paying its suppliers.
Jubilant Pharmova Days Payable Related Terms
Jubilant Pharmova Days Payable Historical Data
* Premium members only.
The historical data trend for Jubilant Pharmova's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Jubilant Pharmova's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jubilant Pharmova Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jubilant Pharmova's Days Payable distribution charts can be found below:
* The bar in red indicates where Jubilant Pharmova's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Jubilant Pharmova's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jubilant Pharmova (BOM:530019) has a Days Payable of 157.87 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Jubilant Pharmova and its competitors. This is 31% above median its historical median of 120.23. Over the past decade, Jubilant Pharmova's Days Payable has ranged from 102.98 to 233.67. According to the industry distribution chart, Jubilant Pharmova ranks #230 out of 925 companies in the Drug Manufacturers industry, placing it in the top 24.9%.
Is Jubilant Pharmova's Days Payable too high?
Jubilant Pharmova's current Days Payable of 157.87 is 31% above median its 10-year median of 120.23. Over the past 10 years, this metric has ranged from a low of 102.98 to a high of 233.67. The Drug Manufacturers industry median Days Payable is 90.38. Jubilant Pharmova's value of 157.87 is 74.7% above this industry median. Based on the distribution chart, Jubilant Pharmova ranks #230 out of 925 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jubilant Pharmova has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jubilant Pharmova's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jubilant Pharmova ranks #230 out of 925 companies for Days Payable. This places Jubilant Pharmova in the top 25% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.38. Jubilant Pharmova's value of 157.87 is 74.7% above this benchmark. Historically, Jubilant Pharmova's own Days Payable has ranged from 102.98 to 233.67 over the past decade. While the company's 10-year median is 120.23 vs. the industry median of 90.38, Jubilant Pharmova has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jubilant Pharmova's current Days Payable of 157.87 is 74.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Jubilant Pharmova and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jubilant Pharmova's current Days Payable is 157.87, which is 31% above median its own 10-year median of 120.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jubilant Pharmova stock overvalued right now?
Based on GuruFocus' analysis, Jubilant Pharmova (BOM:530019) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,060.00, compared to a current price of ₹1,022.25 — trading 3.6% below its estimated fair value. The current Days Payable is 157.87, which is 31% above median its 10-year median of 120.23 and 74.7% above the Drug Manufacturers industry median of 90.38. Jubilant Pharmova's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Jubilant Pharmova (BOM:530019), the current Days Payable is 157.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jubilant Pharmova (BOM:530019) Overvalued in 2026?
Based on GuruFocus' analysis, Jubilant Pharmova stock appears to be undervalued.
The current stock price of ₹1,022.25 is trading 3.6% below its estimated GF Value™ of ₹1,060.00.
GuruFocus considers Jubilant Pharmova to be Fairly Valued.
Key valuation signals for BOM:530019:
Days Payable: 157.87 (31% above median its 10-year median of 120.23)
GF Value™: ₹1,060.00 vs. price of ₹1,022.25 (3.6% below fair value)
Industry Position: 74.7% above the Drug Manufacturers median (#230 of 925)
No single metric tells the full story. See the BOM:530019 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jubilant Pharmova Ltd is an integrated pharmaceutical company. The company operates in the following segments; Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research, Development and Manufacturing Organisation; and Proprietary Novel Drugs. It generates maximum revenue from the Radiopharma segment which specializes in developing, manufacturing, commercializing, and distributing therapeutic agents in the nuclear medicine domain. Geographically, it derives a majority of its revenue from the Americas and Europe and the rest from India and the Rest of the world.
71GF Score
Get the complete analysis for BOM:530019
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530019 has been successfully added to your 
